The past three decades have borne witness to many advances in the understanding of the
molecular biology and treatment of nasopharyngeal carcinoma (NPC), an Epstein–Barr virus …

Nasopharyngeal carcinoma (NPC) is a metastasis-prone malignancy closely associated
with the Epstein–Barr virus (EBV). Despite ubiquitous infection of EBV worldwide, NPC …

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the
nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these …

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M
NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC …

The worldwide burden of cancer is substantial and growing. More than one in six deaths
globally are due to cancer, with 19 million new cancer cases and 10 million new cancer …

Importance There are currently no therapies approved by the US Food and Drug
Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is the current …

Radiotherapy is a valid treatment for nasopharyngeal carcinoma (NPC), and radioresistance
is the main cause of local NPC treatment failure. However, the underlying mechanisms and …

Epstein–Barr virus (EBV) was the first tumor virus in humans. Nasopharyngeal carcinoma
(NPC) accounts for approximately 60% of the 200,000 new tumor cases caused by EBV …

Introduction Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southeast
Asia, particularly Southern China. The classical non-keratinising cell type is almost …

Background Pembrolizumab previously demonstrated robust antitumor activity and
manageable safety in a phase Ib study of patients with heavily pretreated, programmed …